Urological malignancies and the proteomic-genomic interface.
The urological malignancies, renal, bladder and prostate cancer, account for approximately 16% of all cancer cases. Unfortunately 5-year survival rates are relatively poor, largely a result of many cases not being diagnosed before the tumour has metastasised. There is a clear need for the identification of markers which will allow earlier detection of disease, and predict prognosis and response to therapy. In addition, they may be of use as therapeutic targets. Current advances in molecular biology are allowing the identification of a number of tumour-associated changes which could be of clinical use in the future. However, with the rapid technological advances being made in the field of proteomics, this approach could be integrated with genomics providing a complementary alternative, overcoming disparities between mRNA levels and protein production, and additionally allowing the identification of tumour-associated post-translational modifications. These approaches have already been used to identify novel genes and other cancer-related changes involved in the pathogenesis of urological malignancies. This review describes current progress in the genomic and proteomic study of urological malignancies, and highlights the potential of using proteomic technologies in the study of this group of diseases.
Unwin
R D
RD
ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds, UK.
Knowles
M A
MA
Selby
P J
PJ
Banks
R E
RE
D016678:Genome; D006801:Humans; D008297:Male; D008491:Medical Informatics Applications; D009154:Mutation; D011471:Prostatic Neoplasms / Q000235:genetics*; D020543:Proteome; D014571:Urologic Neoplasms / Q000235:genetics*
D020543:Proteome